Topical bovine thrombin and adverse events: A review of the literature

Current Medical Research and Opinion

Volumn 24, Issue 7, 2008, Pages 2071-2087

  Clark, John ^a   Crean, Sheila ^a   Reynolds, Matthew W ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Adverse event; Bovine; Safety; Surgery; Thrombin

Indexed keywords

ATROPINE; AUTOANTIBODY; BLOOD CLOTTING FACTOR 5; CROSS REACTING ANTIBODY; EPHEDRINE; FIBRIN GLUE; FLOSEAL; FRESH FROZEN PLASMA; GELFOAM; HEPARIN; IMMUNOGLOBULIN; PROTHROMBIN; THROMBIN; THROMBOSTAT; VITAMIN K GROUP; WARFARIN;

ABDOMINAL BLEEDING; ABDOMINAL HYSTERECTOMY; ABSCESS; ALBUMIN BLOOD LEVEL; ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANEMIA; ANTIBODY PRODUCTION; AORTA DISSECTION; ARTERY THROMBOSIS; BACTERIAL ENDOCARDITIS; BLEEDING; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BLOOD CLOTTING TIME; BLOOD TRANSFUSION REACTION; BOVINE THROMBIN TIME; BRADYCARDIA; BRAIN INFARCTION; BYPASS OCCLUSION; CLINICAL RESEARCH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CORONARY ARTERY BYPASS GRAFT; CROSS REACTION; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; EPISTAXIS; FALSE ANEURYSM; FEVER; GASTROINTESTINAL HEMORRHAGE; GRAFT STENOSIS; HEART ARREST; HEMATEMESIS; HEMATOTHORAX; HEMATURIA; HEMODIALYSIS; HEMORRHAGIC PERICARIDITIS; HEMORRHAGIC STROKE; HEMOSTASIS; HUMAN; HYPERCOAGULATION; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; KIDNEY FAILURE; LAMINECTOMY; LENGTH OF STAY; LIVER RESECTION; LUNG EMBOLISM; LUNG HEMORRHAGE; MEDIASTINITIS; MELENA; MESENTERIC ARTERY THROMBOSIS; METHODOLOGY; MULTIPLE ORGAN FAILURE; NAUSEA; PAIN; PARTIAL THROMBOPLASTIN TIME; PERICARDIAL HEMATOMA; PERIPHERAL EDEMA; PLASMAPHERESIS; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDY; PROTHROMBIN TIME; PUBLICATION; QUANTITATIVE STUDY; RECTUM HEMORRHAGE; REOPERATION; RETROPERITONEAL HEMATOMA; RETROSPECTIVE STUDY; REVIEW; RISK; RISK FACTOR; SALPINGOOOPHORECTOMY; SEROMA; SIDE EFFECT; SPINE FUSION; STROKE; SUTURE; SYSTEMATIC REVIEW; THROMBIN TIME; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOEMBOLIC STROKE; THROMBOEMBOLISM; THROMBOPHLEBITIS; THROMBOPLASTIN TIME; TRANSITIONAL BLINDNESS; ULCER; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; WOUND DRAINAGE; WOUND INFECTION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIBODY FORMATION; CATTLE; HEMOSTATICS; HUMANS; THROMBIN;

EID: 47949115787     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802186417     Document Type: Review

References (47)

1. Chambers RC, Leoni P, Blanc-Brude OP, et al. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor - 1. J Biol Chem 2000;275:35584-91
2. Jackson MR, MacPhee MJ, Drohan WN, et al. Fibrin sealant: current and potential clinical applications. Blood Coagul Fibrinolysis 1996;7:737-46
3. Alving BM, Weinstein MJ, Finlayson JS, et al. Fibrin sealant: summary of a conference on characteristics and clinical uses. Transfusion 1995;35:783-90
4. Dorion RP, Hamati HF, Landis B, et al. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med 1998;122:887-94
5. von Oppell UO, Zilla P. Tissue adhesives in cardiovascular surgery. J Long Term Eff Med Implants 1998;8:87-101
6. Lundblad RL, Bradshaw RA, Gabriel D, et al. A review of the therapeutic uses of thrombin. Thromb Haemost 2004;91:851-60
7. Uy HS, Reyes JM, Flores JD, et al. Comparison of fibrin glue and sutures for attaching conjunctival autografts after pterygium excision. Ophthalmology 2005;112:667-71
8. Marticorena J, Rodriguez-Ares MT, Tourino R, et al. Pterygium surgery: conjunctival autograft using a fibrin adhesive. Cornea 2006;25:34-6
9. Ortel TL, Charles LA, Keller FG, et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol 1994;45:128-35
10. Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006;32-Suppl 1:98-110
11. Winterbottom N, Kuo J, Nguyen K, et al. Antigenic responses to bovine thrombin exposure during surgery: a prospective study of 309 patients. J Appl Res 2002;2:1-11
12. Ortel TL, Mercer MC, Thames EH, et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001;233:88-96
13. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9:418-35
14. Flaherty MJ, Henderson R, Wener MH. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann Intern Med 1989;111:631-4
15. Rapaport SI, Zivelin A, Minow RA, et al. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992;97:84-91
16. Spero JA. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J Neurosurg 1993;78:817-20
17. Israels SJ, Israels ED. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am J Pediatr Hematol Oncol 1994;16:249-54
18. Cruickshank MK, Black J, Wall W. Development of a factor V and thrombin inhibitor following partial hepatic resection and the use of topical thrombin concentrate. Clin Lab Haematol 1994;16:187-90
19. Tarantino MD, Ross MP, Daniels TM, et al. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin. J Pediatr Hematol Oncol 1997;19:226-31
20. Chouhan VD, De La Cadena RA, Nagaswami C, et al. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost 1997;77:343-9
21. Zumberg MS, Waples JM, Kao KJ, et al. Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant. Am J Hematol 2000;64:59-63
22. Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990;76:2011-6
23. Christie RJ, Carrington L, Alving B. Postoperative bleeding induced by topical bovine thrombin: report of two cases. Surgery 1997;121:708-10
24. Kajitani M, Ozdemir A, Aguinaga M, et al. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg 2000;15:378-82
25. Sarfati MR, Dilorenzo DJ, Kraiss LW, et al. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg 2004;18:349-51
26. Berruyer M, Amiral J, Ffrench P, et al. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg 1993;105:892-7
27. Caers J, Reekmans A, Jochmans K, et al. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer. Endoscopy 2003;35:542-4
28. Cmolik BL, Spero JA, Magovern GJ, et al. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg 1993; 105:222-7[discussion 7-8]
29. Diez-Martin J, Sikkink RA, Gilchrist GS, et al. Development of anti-bovine thrombin antibodies following neurosurgical procedures. Br J Haematol 1990;74:369-70
30. Muntean W, Zenz W, Finding K, et al. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child. Acta Paediatr 1994;83:84-7
31. Adams JD, Jones S, Brost BC. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report. J Reprod Med 2001;46:909-12
32. Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002;42:18-26
33. Poynton AR, Nelson MC, McCance SE, et al. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases. Spine 2003;28:E2211-E223
34. La Spada AR, Skalhegg BS, Henderson R, et al. Brief report: fatal hemorrhage in a patient with an acquired inhibitor of human thrombin. New Engl J Med 1995;333:494-7
35. Berguer R, Staerkel RL, Moore EE, et al. Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports. J Trauma 1991;31:408-11
36. Rothenberg DM, Moy JN. Anaphylactic reaction to topical bovine thrombin. Anesthesiology 1993;78:779-82
37. Wai Y, Tsui V, Peng Z, et al. Anaphylaxis from topical bovine thrombin (Thrombostat) during haemodialysis and evaluation of sensitization among a dialysis population. Clin Exp Allergy 2003;33:1730-4
38. Banninger H, Hardegger T, Tobler A, et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 1993;85:528-32
39. Carroll JF, Moskowitz KA, Edwards NM, et al. Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent. Thromb Haemost 1996;76:925-31
40. Schoenecker JG, Hauck RK, Mercer MC, et al. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose. J Clin Immunol 2000;20:434-44
41. Fastenau DR, Wagenknecht DR, Hormuth DA, et al. Left ventricular assist system recipients exposed to bovine thrombin preparations have a higher frequency of antiphospholipid antibodies than non-exposed recipients. ASAIO J 2001;47:537-40
42. Nelson PA, Powers JN, Estridge TD, et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res 2001;58:710-9
43. Sands JJ, Nudo SA, Moore KD, et al. Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis. ASAIO J 2001;47:507-10
44. Su Z, Izumi T, Thames EH, et al. Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. J Lab Clin Med 2002;139:349-56
45. Favaloro EJ, Posen J, Ramakrishna R, et al. Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis 2004;15:637-47
46. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 2007;205:256-65
47. Mathiasen RA, Cruz RM. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in children undergoing adenoidectomy. Otolaryngol Head Neck Surg 2004;131:601-5